Clinical Trial Search

Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants

Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…

Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day

Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale

Primary: Likelihood of Accruing Participants: Feasibility of Enrollment — 27; 24 Participants

Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions

Primary: Change From Baseline Insomnia Severity Index Score at Study Completion — 11.2; 12.6; 6.0; 8.8 units on a scale — p=0.0041

Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale

Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: App Feasibility — 122 Participants

Primary: Global Cognitive Ability (GCA) — -1.99; -0.82 Standard score (Z-score) — p=0.005

Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Primary: Change in Anxiety: Depression Anxiety Stress Scale (DASS21). — 9.38; 10.1; 10.5; 9.85 units on a scale

Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed

Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33

Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants

Primary: Alpha Learning Rate — .62; .43; .55; .21 Alpha Coefficient

Primary: Continuous Abstinence Via Progressive Declines in Urine THCCOOH — NA ng/mL

Primary: Cannabis Use — 55.89; 63.10 Percentage of use days

Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale

Primary: Change in Kessler Psychological Distress Scale (K10) Score — 6.4; 4.5 score on a scale

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 10.21; 10.2 joints smoked during the prior week — p=.99

Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale

Primary: Change in Cold Pressor Test (CPT) Latency — 21.40; 10.94; 2.07; 15.17 percent change from Day 1 baseline

Primary: Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks — 0.39; 0.12 score on a scale — p=<0.001

Primary: Mean Difference in the Total Number of Errors From Paired Associates Learning (PAL) Module Averaged Over Weeks 1, 2, 3, and 4 — 5.6; 6.2; 5.9 score on a scale — p=0.215

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Pain Interference: Roland Morris Disability Questionnaire (RMDQ) — 8.028; 9.635; 9.034; 6.194 score on a scale